The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on photodynamic therapy for localised inoperable endobronchial cancer.
Photodynamic therapy is a minimally invasive treatment, involving injection of a photosensitising agent, followed a few days later by photo-radiation to the affected area through a bronchoscope. This is intended to reduce the bulk of the tumour, thus reducing symptoms caused by bronchial obstruction. PDT is performed endobronchially, with debridement of necrotic tumour within a few days of each treatment.
E48.7 Fibreoptic endoscopic photodynamic therapy of lesion of lower respiratory tract
Chapter ‘Z’ code for site in lower respiratory tract
In addition an ICD-10 code from category C34.- Malignant neoplasm of bronchus and lung or C78.0 Secondary malignant neoplasm of lung is assigned.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.